Sector News

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

January 23, 2021
Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Adagene is built on a platform designed to expand the available binding sites well beyond what is possible with conventional natural or synthetic antibodies. Working with the platform, Adagene has developed candidates it thinks have an edge over other drugs targeting CD137 and CTLA-4.

Drug developers including Bristol Myers Squibb and Pfizer are working on drugs against CD137, the target of ADG106. What sets ADG106 apart, according to Adagene, is its targeting of a unique conserved epitope of CD137 that gives it a novel mechanism of action. An end of phase 1 meeting for a clinical trial of ADG106 in solid tumors is scheduled for this quarter.

Two drugs targeting CTLA-4, ADG126 and ADG116, are following Adagene down the pipeline. The drugs, both of which are in phase 1, are based on different technologies. Adagene plans to focus on ADG126, the first asset generated using its SAFEbody technology.

SAFEbody is designed to prevent an antibody from binding to its target in healthy tissues. Antibodies featuring the technology should only bind to their targets when exposed to conditions found in the tumor microenvironment. Adagene has applied the technology to CTLA-4 in the belief it can better the safety of existing antibodies against the target, notably Bristol Myers’ Yervoy.

Around one-quarter of the IPO money will fund phase 1 development and the advancement into phase 2 for ADG106, with another quarter supporting the same work on ADG126 and ADG116. Most of the rest of the money is earmarked for the development of the platform and preclinical programs.

by Nick Paul Taylor

Source: fiercebiotech.com

Related News

May 1, 2021

AbbVie remains one of the best buys in its sector

Life sciences

AbbVie will be among the stocks closing out a busy earnings week. Earnings season tends to draw a lot of interest from investors, but it’s not always the best indicator of a stock’s overall trajectory.

May 1, 2021

Pfizer buys infectious disease biotech Amplyx

Life sciences

Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns more toward infectious diseases.

May 1, 2021

Medtronic taps virtual reality ‘flight simulators’ for brain surgery, built from 3D patient scans

Life sciences

Surgical Theater’s technology builds 3D models of an individual patient’s anatomy from CT and MRI scans to offer surgeons an immersive, 360-degree fly-through view.

Send this to a friend